Citations

Showing 10 of 108162 citations.

Enrichment of Neurodegenerative Microglia Signature in Brain-Derived Extracellular Vesicles Isolated from Alzheimer’s Disease Mouse Models
Muraoka, Satoshi , Jedrychowski, Mark P., Iwahara, Naotoshi , Keezer, Kelly J., Hu, Jianqiao, Ikezu, Seiko , Howell, Gareth R. , Gygi, Steven P. , Ikezu, Tsuneya , Gygi, Steven P , Ikezu, Tsuneya , Abdullah, Mohammad, Onos, Kristen D.

Mayo Clinic

Journal of Proteome Research | February 6, 2021 | Volume: 20 | Issue: 3 | Pages: 1733-1743

10.1021/acs.jproteome.0c00934 | PMID 33534581 Get It

Effects of Covid‐19: The Need to Assess the Real Value of Anatomy Education
Pawlina, Wojciech, Evans, Darrell J. R.

Mayo Clinic

Anatomical Sciences Education | February 6, 2021 | Volume: 14 | Issue: 2 | Pages: 129-131

10.1002/ase.2061 | PMID 33547880 Get It

Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa
Price, Kyla N. , Collier, Erin K. , Fernandez, Jennifer M. , Alhusayen, Raed , Porter, Martina J., Hsiao, Jennifer L. , Shi, Vivian Y. , Fernandez, Jennifer M , Hsiao, Jennifer L , Shi, Vivian Y , Grogan, Tristan , Alavi, Afsáneh , Hamzavi, Iltefat H. , Lowes, Michelle A

Mayo Clinic

Dermatologic Therapy | February 6, 2021 | Volume: 34 | Issue: 2 | Pages: No page available

10.1111/dth.14851 | PMID 33547869 Get It

Abstract Hidradenitis suppurativa (HS) is a chronic and often debilitating inflammatory condition characterized by frequent nodules, abscesses, sinus tracts, and scars impacting the intertriginous areas. Many patients with HS often report limited treatment success and symptom coverage with conventional therapies. Recent studies have reported the widespread use of complementary and alternative medicine (CAM) among patients with HS. In this study, our aim was to examine current physician practice patterns, opinions, and comfort with recommending CAM. Our results indicate that provider comfort and opinions on CAM varied based on the provider's experiences, demographics, and the CAM modality itself. Overall, nearly two‐thirds (n = 30, 61.2%) of respondents agreed that CAM and conventional medicine were more effective together than either alone. Meanwhile, 44.9% (n = 22) of respondents routinely recommend CAM while 64.6% (n = 31) of respondents reported that they are routinely asked about CAM. The majority (n = 41, 83.7%) of respondents indicated a lack of scientific evidence in the medical literature as a barrier to recommending CAM along with efficacy concerns (n = 34, 69.4%) and ability to recommend reputable CAM products (n = 32, 65.3%) and practitioners (n = 32, 65.3%). Future investigations are warranted to establish a better understanding of the efficacy and benefit of CAM methods in conjunction with conventional methods.
Underreporting of Vestibular Schwannoma Incidence Within National Brain Tumor and Cancer Registries in the United States
Marinelli, John P. , Nassiri, Ashley M. , Habermann, Elizabeth B. , Lohse, Christine M. , Carlson, Matthew L. , Holton, Sara J, Habermann, Elizabeth , Holton, Sara J.

Mayo Clinic

Otology & Neurotology | February 6, 2021 | Volume: 42 | Issue: 6 | Pages: e758-e763

10.1097/mao.0000000000003049 | PMID 34111053 Get It

Objective: Reports using large brain tumor and cancer registries suggest that the incidence of vestibular schwannoma is considerably lower in the United States compared with other countries. The current study compares the incidence and disease characteristics of vestibular schwannoma within a large tertiary referral center's brain tumor and cancer registry using nationally mandated reporting protocols to disease incidence in the same population using an externally validated population-based consortium. Study Design: Population-based study spanning 1,945,007 person-years. Setting: Large tertiary referral center. Patients: Adults with sporadic vestibular schwannoma. Main Outcome Measure: Disease incidence rates from 2004 to 2016. Results: From 2004 to 2016, the incidence of vestibular schwannoma in the tumor registry was 1.3 per 100,000 person-years whereas the population-based cohort had an incidence of 4.4 per 100,000 person-years. From 2012 to 2016, the incidence in the tumor registry was 1.4 per 100,000 person-years compared with 5.2 in the population-based cohort. Patients within the population-based cohort were significantly more likely to have smaller tumors at diagnosis (78% intracanalicular versus 45%; p = 0.004) and consequently more likely to undergo management consisting of observation with serial imaging as opposed to treatment with either microsurgery or radiosurgery (71% versus 28%; p = 0.001). Conclusions: The reliance on pathology specimens and cancer-related treatment data for the national registration of new cancer and brain tumor diagnoses may introduce selection bias and underreporting of benign brain tumors that frequently involve observation as a primary treatment modality. This selection bias likely accounts for the discrepant incidence rates of vestibular schwannoma reported between the United States and other countries.
Medical and Endoscopic Management of Crohn Disease
Deepak, Parakkal , Ludwig, Daniel R. , Fidler, Jeff L. , Guglielmo, Flavius F. , Bruining, David H. , Deepak, Parakkal , Guglielmo, Flavius F , Fidler, Jeff L.

Mayo Clinic

Topics in Magnetic Resonance Imaging | February 6, 2021 | Volume: 30 | Issue: 1 | Pages: 43-61

10.1097/rmr.0000000000000267 | PMID 33528211 Get It

Abstract In this review, through a series of questions and answers, we explore the current approach to classifying patients with Crohn disease into low-risk (mild-moderate) and high-risk (moderate-severe) categories with the recommended treatment approaches per guidelines from the International Organization for the Study of Inflammatory Bowel Diseases, American Gastroenterological Association, the American College of Gastroenterology, and the European Crohn's and Colitis Organization detailed here. The development pipeline of potential therapies is also summarized. We also review key information from magnetic resonance enterography and pelvis imaging studies that the abdominal radiologist can communicate to a multidisciplinary treatment team that includes gastroenterologists and colorectal surgeons, with a goal of achieving optimal patient outcomes. Lastly, endoscopic and radiological treatment targets in a treat-to-target approach in Crohn disease are explored.
State of the Art MR Enterography Technique
Chatterji, Manjil, Fidler, Jeff L. , Taylor, Stuart A. , Anupindi, Sudha A. , Yeh, Benjamin M. , Guglielmo, Flavius F. , Guglielmo, Flavius F , Fidler, Jeff L.

Mayo Clinic

Topics in Magnetic Resonance Imaging | February 6, 2021 | Volume: 30 | Issue: 1 | Pages: 3-11

10.1097/rmr.0000000000000263 | PMID 33528207 Get It

Abstract Magnetic resonance enterography (MRE) is a well-established imaging technique that is commonly used for evaluating a variety of bowel diseases, most commonly inflammatory bowel disease which is increasing in prevalence. Inflammatory bowel disease is composed of 2 related, but distinct disease entities: Crohn disease (CD) and ulcerative colitis. In ulcerative colitis, inflammation is generally limited to the mucosa and invariably involves the rectum, and often the more proximal colon. CD is typified by transmural inflammation with skip lesions occurring anywhere from the mouth to anus, but characteristically involves the terminal ileum. The transmural involvement of CD may lead to debilitating ulceration and, ultimately, development of sinus tracts, which can be associated with abscesses and fistulae as extraenteric manifestations of the disease. Because much of the small bowel and extraenteric disease cannot be adequately assessed with conventional endoscopy, imaging plays a crucial role in initial diagnosis and follow-up. MRE does not use ionizing radiation which is important for these patients, many of which present earlier in life and may require multiple imaging examinations. In this article, we review the clinical indications, patient preparation, and optimal technique for MRE. We also discuss the role and proper selection of intravenous gadolinium-based contrast material, oral contrast material, and antiperistaltic agents, including pediatric considerations. Finally, we review the recommended and optional pulse sequence selection, including discussion of a “time-efficient” protocol, reviewing their utility, advantages, and limitations. Our hope is to aid the radiologist seeking to develop a robust MRE imaging program for the evaluation of bowel disease.
In‐office insertion tympanostomy tubes in children using single‐pass device
Truitt, Theodore O. , Kosko, James R., Nimmons, Grace L., Raisen, Jay , Skovlund, Sandra M., Rimell, Frank L., Cofer, Shelagh A.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | February 6, 2021 | Volume: 6 | Issue: 2 | Pages: 325-331

10.1002/lio2.533 | PMID 33869765 Get It

Abstract Objectives Insertion of tympanostomy tubes (TT) is generally accomplished in children in the operating room under general anesthesia. We report on 229 children treated in‐office with a novel device. Methods Investigators participated in an IRB‐approved, prospective, single arm, multisite investigation of in‐office TT placement in awake children. Topical anesthetic was applied, and protective restraint was used. TT placement was performed with a single‐pass TT insertion device. Safety was assessed by monitoring procedural events. Results Four hundred and forty‐four ears were treated in 229 children at 10 sites. Children were in age groups 6‐24 months (n = 211, mean = 13 months) and 5‐12 years (n = 18, mean = 8.3 years). Two hundred and fifteen children received bilateral TT placement, and 14 received unilateral placement. Overall, 226/229 (98.7%) children had successful TT placement in the office (209/211 in 6‐24 months and 17/18 in 5‐12 years). Three children were rescheduled for the operating room due to anatomical challenges or patient movement. Median procedure time for bilateral cases in both age groups was 4:53. Two minor adverse events (AEs) were reported in one patient. Per independent assessment of 30 procedure videos by clinicians, TT placement was tolerated acceptably by all children. Conclusion In‐office TT placement in awake young children using topical anesthetic, enabled by a single pass delivery device, was safe, successful and well tolerated. The American Academy of Otolaryngology (AAO) recently released a Position Statement supporting in‐office TT placement in appropriate children. These results affirm an in‐office alternative for clinicians and parents who have concerns with the risk, inconvenience and cost of surgery in an operating room under general anesthesia. Level of Evidence: 2c. Clinical Trials Registration Number: NCT03544138.
Bacitracin Testing for Group A Streptococcal Pharyngitis
Dale, Jane C.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 5, 2021 | Volume: 127 | Issue: 8 | Pages: 922-923

10.5858/2003-127-922b-btfgas | PMID 12873160 Get It

Prediction of post‐vaccination Guillain‐Barré syndrome using data from a passive surveillance system
Luo, Chongliang , Jiang, Ying , Du, Jingcheng , Re, Vincent Lo , Ellenberg, Susan S. , Tao, Cui , Chen, Yong , Tao, Cui , Tong, Jiayi , Huang, Jing Yang , Poland, Gregory A.

Mayo Clinic

Pharmacoepidemiology and Drug Safety | February 5, 2021 | Volume: 30 | Issue: 5 | Pages: 602-609

10.1002/pds.5196 | PMID 33533072 Get It

AbstractPurposeSevere adverse events (AEs), such as Guillain‐Barré syndrome (GBS) occur rarely after influenza vaccination. We identify highly associated AEs with GBS and develop prediction models for GBS using the US Vaccine Adverse Event Reporting System (VAERS) reports following trivalent influenza vaccination (FLU3).MethodsThis study analyzed 80 059 reports from the US VAERS between 1990 and 2017. Several AEs were identified as highly associated with GBS and were used to develop the prediction model. Some common and mild AEs that were suspected to be underreported when GBS occurred simultaneously were removed from the final model. The analyses were validated using European influenza vaccine AEs data from EudraVigilance.ResultsOf the 80 059 reports, 1185 (1.5%) were annotated as GBS related. Twenty‐four AEs were identified as having strong association with GBS. The full prediction model, using age, sex, and all 24 AEs achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 85.4% (90% CI: [83.8%, 86.9%]). After excluding the nine (e.g., pruritus, rash, injection site pain) likely underreported AEs, the final AUC became 77.5% (90% CI: [75.5%, 79.6%]). Two hundred and one (0.25%) reports were predicted as of high risk of GBS (predicted probability >25%) and 84 actually developed GBS.ConclusionThe prediction performance demonstrated the potential of developing risk‐prediction models utilizing the VAERS cohort. Excluding the likely underreported AEs sacrificed some prediction power but made the model more interpretable and feasible. The high absolute risk of even a small number of AE combinations suggests the promise of GBS prediction within the VAERS dataset.
Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma
Goswami, Julie , Bailey, Kent R. , Spears, Grant M. , Kozar, Rosemary A. , Dong, Jing‐fei , Heller, Stephanie F. , Loomis, Erica, Hall, Nathan W , Johnstone, Andrea L. , Park, Myung S., MacArthur, Taleen, Spears, Grant, Auton, Matthew , Heller, Stephanie, MacArthur, Taleen A. , Key, Nigel S.

Mayo Clinic

Shock | February 5, 2021 | Volume: 56 | Issue: 3 | Pages: 433-439

10.1097/shk.0000000000001741 | PMID 33534396 Get It

ABSTRACT Background: Damage-associated molecular patterns (DAMPs) stimulate endothelial syndecan-1 shedding and neutrophil extracellular traps (NET) formation. The role of NETs in trauma and trauma-induced hypercoagulability is unknown. We hypothesized that trauma patients with accelerated thrombin generation would have increased NETosis and syndecan-1 levels. Methods: In this pilot study, we analyzed 50 citrated plasma samples from 30 trauma patients at 0 h (n = 22) and 6 h (n = 28) from time of injury (TOI) and 21 samples from healthy volunteers, for a total of 71 samples included in analysis. Thrombin generation was quantified using calibrated automated thrombogram (CAT) and reported as lag time (LT), peak height (PH), and time to peak (ttPeak). Nucleosome calibrated (H3NUC) and free histone standardized (H3Free) ELISAs were used to quantify NETs. Syndecan-1 levels were quantified by ELISA. Results are presented as median [interquartile range] and Spearman rank correlations. Results: Plasma levels of H3NUC were increased in trauma patients as compared with healthy volunteers both at 0 h (89.8 ng/mL [35.4, 180.3]; 18.1 ng/mL [7.8, 37.4], P = 0.002) and at 6 h (86.5 ng/mL [19.2, 612.6]; 18.1 ng/mL [7.8, 37.4], P = 0.003) from TOI. H3Free levels were increased in trauma patients at 0 h (5.74 ng/mL [3.19, 8.76]; 1.61 ng/mL [0.66, 3.50], P = 0.002) and 6 h (5.52 ng/mL [1.46, 11.37]; 1.61 ng/mL [0.66, 3.50], P = 0.006). Syndecan-1 levels were greater in trauma patients (4.53 ng/mL [3.28, 6.28]; 2.40 ng/mL [1.66, 3.20], P < 0.001) only at 6 h from TOI. H3Free and syndecan-1 levels positively correlated both at 0 h (0.376, P = 0.013) and 6 h (0.583, P < 0.001) from TOI. H3NUC levels and syndecan-1 levels were positively correlated at 6 h from TOI (0.293, P = 0.041). TtPeak correlated inversely to H3 NUC (−0.358, P = 0.012) and syndecan-1 levels (−0.298, P = 0.038) at 6 h from TOI. Conclusions: Our pilot study demonstrates that trauma patients have increased NETosis, measured by H3NUC and H3Free levels, increased syndecan-1 shedding, and accelerated thrombin generation kinetics early after injury.